The PANORAMA results suggest that treatment with anti-VEGF injections can regress diabetic retinopathy (DR) severity and lower the likelihood of diabetic macular edema. Rates of anti-VEGF therapy use have increased since the publication of Protocol S, whereas rates of panretinal photocoagulation have decreased nationwide.

To evaluate the efficacy and safety of anti-VEGF and panretinal photocoagulation (PRP) for the treatment of proliferative diabetic retinopathy (PDR). The outcomes examined are changes in best-corrected visual acuity (BCVA), neovascularization (NV), central macular thickness (CMT), and adverse outcomes.

Oct 1, 2024 · In this retrospective cohort study, findings suggest that patients with PDR treated with PRP first then subsequent anti-VEGF injection are more likely to undergo PPV for VH and TRD compared with matched patients treated with anti-VEGF agents first, then PRP.

Treatment with PRP and subsequent anti-VEGF injection was associated with higher rates of VH at 5 years (RR, 1.40; 95% CI, 1.09-1.80; RD, 6.47%; 95% CI, 1.66%-11.29%; P < .001) and TRD at 5 years (RR, 1.85; 95% CI, 1.35-2.53; RD, 4.31%; 95% CI, 2.10%-6.52%; P < .001), with similar findings at 6 months, 1 year, and 3 years compared with patients ...

Feb 21, 2022 · Anti-VEGF medications have proved to be an important breakthrough in the treatment of PDR. The studies discussed above have demonstrated that anti-VEGF can be used as an adjunct to PRP, if not as a replacement. Almost all the outcomes favor anti-VEGF, with improved gains in VA.

Altogether, recent data suggests that in patients with PDR, anti-VEGF is superior to PRP in terms of visual acuity benefit, DME prevention, adverse effect of visual field loss, and the need for future PPV or additional PRP.

Feb 25, 2019 · Our institution recently looked at rates of lost to follow-up (LTFU) in 2,302 patients with proliferative diabetic retinopathy after receiving either anti-VEGF vs. PRP. 6. We found that about a quarter of patients with PDR were LTFU after at least one treatment session for a …

Jun 1, 2021 · The study analyzes the impact of the 2015 publication of DRCR Retina Network Protocol S on the utilization of intravitreal anti-VEGF injections as an alternative to PRP for the treatment of proliferative diabetic retinopathy, highlighting significant changes in …

Jun 11, 2024 · PRP has fallen out of favor in recent years as anti-VEGF is more sparing of the retina and generally safer, with comparable results. This study showed differences in complication rates between the two.

For the past 4 decades, treatment of high-risk PDR has traditionally involved DRS-style PRP. The advent of anti-VEGF agents has introduced new alternatives by targeting a key downstream effector of PRP therapy—VEGF secreted by retinal tissue in response to …